Description
Saphnelo (anifrolumab) is a monoclonal antibody used for the treatment of adult patients with systemic lupus erythematosus (SLE). Saphnelo targets the type I interferon receptor subunit 1 (IFNAR1) and is administered intravenously.
Uses:
Saphnelo is used to treat adult patients with SLE, a chronic autoimmune disease in which the immune system attacks healthy tissues. SLE affects many organs and can lead to serious health problems. Saphnelo works by blocking the activity of type I interferons, which are a key component of the immune system activation in SLE.
Storage Conditions:
Saphnelo should be stored in a refrigerator at 2°C to 8°C (36°F to 46°F) until time of use. The medication should be protected from light and should not be frozen or shaken.
Mechanism of Action:
Saphnelo blocks the activity of type I interferons, which are a key component of the immune system activation in SLE. Interferons can promote inflammation and increase the production of autoantibodies in patients with SLE. By blocking the activity of IFNAR1, Saphnelo reduces the abnormal immune activation in patients with SLE.
How to Use:
Saphnelo is administered intravenously every four weeks by a healthcare provider. The dosage and duration of treatment are determined by the healthcare provider based on the patient’s weight and kidney function.
Precautions:
Before taking Saphnelo, patients should inform their healthcare providers of any allergies, medical conditions, and medications they are currently taking. Saphnelo may increase the risk of infections and patients should be monitored for signs of infection. The medication may also cause hypersensitivity reactions, and patients should be monitored for signs of an allergic reaction during administration.
Drug Interactions:
Saphnelo may interact with drugs that affect the immune system or increase the risk of infection. Patients should inform their healthcare providers of any medications they are taking, including over-the-counter medications, vitamins, and supplements, before taking Saphnelo.
Contraindications:
Saphnelo is contraindicated in patients with known hypersensitivity to anifrolumab or any of its components.
Overdose:
In the event of an overdose, patients should contact their healthcare provider.
Adverse Reactions:
The most common adverse reactions reported with Saphnelo include infections, infusion reactions, and rash. Patients should report any adverse reactions to their healthcare provider.
Overall, Saphnelo is a monoclonal antibody used for the treatment of SLE in adults. The medication is administered intravenously every four weeks by a healthcare provider, and the dosage and duration of treatment are determined based on the patient’s weight and kidney function. Patients should inform their healthcare provider of any allergies, medical conditions, and medications they are taking and should be monitored for signs of infection and allergic reaction during administration. Saphnelo may cause adverse reactions such as infections, infusion reactions, and rash and is contraindicated in patients with a known hypersensitivity to anifrolumab or any of its components.
Reviews
There are no reviews yet.